Discover open access scientific publications

Search, annotate, share and cite publications

Publications by H. Daga

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Journal of Thoracic Oncology

English

Related publications

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology

English

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Journal of Thoracic Oncology

English

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology

English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Journal of Clinical Oncology

English

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

English

Changing Paradigm of Immunooncology in Advanced Kidney Cancer: Nivolumab and Ipilimumab Combination in the First Line Therapy

English

Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab

Journal of Cancer Therapy

2015

English

Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by H. Daga

OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227

Related publications

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-Line (1L) Treatment of Advanced NSCLC

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Changing Paradigm of Immunooncology in Advanced Kidney Cancer: Nivolumab and Ipilimumab Combination in the First Line Therapy

Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab

Cost-Effectiveness of Nivolumab (NIVO) Combined With Ipilimumab (IPI) Compared With Nivo and Ipi Monotherapies in the First-Line Treatment of Advanced Melanoma in the United States: Analysis Using 28-Month Overall Survival (OS) Data From Checkmate 067